Press Release
August 31, 2016

MagForce AG attends EANS 2016 from September 4-8 in Athens, Greece

Berlin, Germany and Nevada, USA, August 31, 2016 - MagForce AG (Frankfurt, Entry Standard, XETRA: MF6, ISIN: DE000A0HGQF5), a leading medical device company in the field of nanomedicine focused on oncology, today announced that it will participate in the 16th European Congress of Neurosurgery, EANS 2016, held by the European Association of Neurosurgical Societies from September 4-8, 2016 in Athens, Greece.

MagForce will be represented by a booth (No. 17, level 0) and will be available for questions regarding its NanoTherm™ therapy for the treatment of glioblastoma and other brain tumors. Moreover, the team of Prof Dr Walter Stummer, Director of the Department of Neurosurgery, and the lead investigator of the Post-Marketing study at the University Hospital Münster, will have an oral presentation reporting on experiences with the NanoTherm™ therapy.

Conference Details:
Speaker: Dr Mohammed Jaber, Neurosurgeon, Clinic and Policlinic for Neurosurgery, University Hospital Münster
Title of presentation: “NanoPaste”: Thermotherapy via nanoparticles directly instilled onto glioma resection cavity walls - technique and feasibility
Date of presentation: Tuesday, September 6, 2016; 17:00-19:00 EEST
Location: Megaron Athens International Conference Center, Leoforos Vasilissis Sofias Ave. & Kokkali St. 1, 115 21 Athens, Greece
MagForce booth: No. 17, level 0
Contact: Mohammed.Jaber@ukmuenster.de, uboettcher@magforce.com

About EANS 2016
The European Association of Neurosurgical Societies (EANS) is a fast-developing independent association, both of European neurosurgical societies and of individual neurosurgeons from all over the world which arranges congresses, scientific meetings and symposia, including the biennial European Congress of Neurosurgery, the Annual EANS Meetings and European Training courses.

This year’s congress theme of EANS 2016 is “Neurosurgery: from the Classics to the future." Exploring the past, present and future of the neurosurgical specialty, the European Congress will take an in-depth look at current standards, advances in this field, and gives an outlook for the profession
and developments in neurosurgery. The Scientific Programme will cover the whole neurosurgical spectrum. Invited speakers, most eminent neurosurgeons from both within Europe and throughout the world, will consider the benefits of tried and tested ‘classical’ neurosurgical techniques, comparing them with their cutting-edge alternatives, often minimally invasive techniques.

About MagForce AG and MagForce USA, Inc.
MagForce AG, listed in the entry standard of the Frankfurt Stock Exchange (MF6, ISIN: DE000A0HGQF5), together with its subsidiary MagForce USA, Inc. is a leading medical device company in the field of nanomedicine focused on oncology. The Group’s proprietary NanoTherm™ therapy enables the targeted treatment of solid tumors through the intratumoral generation of heat via activation of superparamagnetic nanoparticles. Mithril Capital Management, a growth-stage technology fund founded by Ajay Royan and Peter Thiel, along with MagForce AG, are investors and strategic partners in MagForce USA, Inc.

NanoTherm™, NanoPlan®, and NanoActivator® are components of the therapy and have received EU-wide regulatory approval as medical devices for the treatment of brain tumors. MagForce, NanoTherm™, NanoPlan®, and NanoActivator® are trademarks of MagForce AG in selected countries.

For more information, please visit: [www.magforce.com](http://www.magforce.com)

Get to know our Technology: [video (You Tube)](#)

Stay informed and subscribe to our [mailing list](#)

For meeting arrangements or any further questions, please contact us at:

**Medical Liaison**
Dr. Ulrike Boettcher  
+49 89 95 477 95-64  
uboettcher@magforce.com

**Media & Investors**
Barbara von Frankenberg  
+49 30 30 83 80-77  
bfrankenberg@magforce.com

**Disclaimer**

This release may contain forward-looking statements and information which may be identified by formulations using terms such as “expects”, “aims”, “anticipates”, “intends”, “plans”, “believes”, “seeks”, “estimates” or “will”. Such forward-looking statements are based on our current expectations and certain assumptions, which may be subject to a variety of risks and uncertainties. The results actually achieved by MagForce AG may substantially differ from these forward-looking statements.
MagForce AG assumes no obligation to update these forward-looking statements or to correct them in case of developments, which differ from those, anticipated.